Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to Strong-Buy

Repligen (NASDAQ:RGEN) was upgraded by Wolfe Research to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other research firms have also issued reports on RGEN. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. Roth Mkm initiated coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. HC Wainwright increased their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Finally, UBS Group reduced their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Stock Performance

NASDAQ RGEN opened at $121.13 on Monday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of 134.59, a P/E/G ratio of 2.37 and a beta of 1.09. The firm’s 50 day simple moving average is $118.05 and its 200 day simple moving average is $139.53. Repligen has a 1 year low of $100.99 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts expect that Repligen will post 1.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RGEN. AQR Capital Management LLC bought a new position in shares of Repligen in the 1st quarter valued at $262,000. Jones Financial Companies Lllp lifted its stake in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after acquiring an additional 20,375 shares during the last quarter. Bank of Nova Scotia lifted its stake in shares of Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after acquiring an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after acquiring an additional 7,148 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.